The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment.

MLA

Sinclair, Susan M., et al. “The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment.” Drug Safety, vol. 40, no. 12, Dec. 2017, pp. 1205–18. EBSCOhost, https://doi.org/10.1007/s40264-017-0566-6.

APA

Sinclair, S. M., Jones, J. K., Miller, R. K., Greene, M. F., Kwo, P. Y., & Maddrey, W. C. (2017). The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment. Drug Safety, 40(12), 1205–1218. https://doi.org/10.1007/s40264-017-0566-6

Chicago

Sinclair, Susan M, Judith K Jones, Richard K Miller, Michael F Greene, Paul Y Kwo, and Willis C Maddrey. 2017. “The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment.” Drug Safety 40 (12): 1205–18. doi:10.1007/s40264-017-0566-6.